Cargando…

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate

PURPOSE: Dengue virus infection is now a global problem. Currently, there is no licensed vaccine or proven antiviral treatment against this virus. All four serotypes (1-4) of dengue virus can infect human. An effective dengue vaccine should be tetravalent to induce protective immune responses agains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fahimi, Hossein, Sadeghizadeh, Majid, Mohammadipour, Mahshid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Vaccine Society 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742598/ https://www.ncbi.nlm.nih.gov/pubmed/26866023 http://dx.doi.org/10.7774/cevr.2016.5.1.41

Ejemplares similares

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
por: Hyatt, James G., et al.
Publicado: (2020)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
por: Azevedo, Adriana S., et al.
Publicado: (2011)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
por: Go, JG, et al.
Publicado: (2009)

In silico Design of a Multivalent Vaccine Against Candida albicans
por: Tarang, Shikha, et al.
Publicado: (2020)

Production of dengue 2 envelope domain III in plant using CPMV - based vector system
por: Carlos Marques, Lívia Érika, et al.
Publicado: (2014)

Multivalent Fusion DNA Vaccine against Brucella abortus
por: Gómez, Leonardo, et al.
Publicado: (2017)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
por: Chivukula, Sudha, et al.
Publicado: (2021)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae
por: So, Kum-Kang, et al.
Publicado: (2021)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

A potent multivalent vaccine for modulation of immune system in atherosclerosis: an in silico approach
por: Karkhah, Ahmad, et al.
Publicado: (2016)

In-silico design of envelope based multi-epitope vaccine candidate against Kyasanur forest disease virus
por: Arumugam, Sathishkumar, et al.
Publicado: (2021)

Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III
por: Zaneti, Arthur Baruel, et al.
Publicado: (2019)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates
por: Campisi, Edmondo, et al.
Publicado: (2021)

Interaction and Inhibition of Dengue Envelope Glycoprotein with Mammalian Receptor DC-Sign, an In-Silico Approach
por: Shah, Masaud, et al.
Publicado: (2013)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Simulation of Hemorrhage Pathogenesis in Mice through Dual Stimulation with Dengue Envelope Protein Domain III-Coated Nanoparticles and Antiplatelet Antibody
por: Lien, Te-Sheng, et al.
Publicado: (2023)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein
por: VanBlargan, Laura A., et al.
Publicado: (2013)

Cardol triene inhibits dengue infectivity by targeting kl loops and preventing envelope fusion
por: Kanyaboon, Parichat, et al.
Publicado: (2018)

An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
por: Ghafouri, Fatemeh, et al.
Publicado: (2020)

A novel strategy for developing vaccine candidate against Jaagsiekte sheep retrovirus from the envelope and gag proteins: an in-silico approach
por: Mahmoud, Nuha Amin, et al.
Publicado: (2022)

Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization
por: Lin, Hsiao-Han, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4r7knu1fhhheqs6n43ckg0b035